By Veronica Grecu
Clayton, N.C.—Fluor Corp.’s Greenville office is under contract to execute the full scope of work on a $2 billion pharmaceutical facility in Clayton, roughly 20 miles from Raleigh. The announcement comes one year and a half since Danish drugmaker Novo Nordisk revealed plans for the new facility and 10 months since Fluor Corp. booked the $1.2 billion value of the investment.
Located near Novo Nordisk’s 23-year-old, 457,000-square-foot plant on Powhatan Road, the new DAPI-US (Diabetes Active Pharmaceutical Ingredients – US) manufacturing facility will produce the active ingredient in a diabetis treatment. The plant will measure more than 830,000 square feet and will employ about 700 people. An estimated 2,500 construction jobs will be created during the construction process, which is set for completion in mid-2019. The facility will become fully operational in 2020.
“This project is the single largest life sciences facility investment in North Carolina’s history, which fits well with Fluor’s legacy of building numerous significant life sciences and manufacturing projects in the southeast United States,” said Juan Hernández, president of Fluor’s life sciences and advanced manufacturing business, in prepared remarks.
Image via Google Street View